StockNews.com Begins Coverage on Ekso Bionics (NASDAQ:EKSO)

Analysts at StockNews.com assumed coverage on shares of Ekso Bionics (NASDAQ:EKSO) in a report issued on Monday. The firm set a “hold” rating on the stock.

Several other research firms have also commented on EKSO. HC Wainwright reduced their price target on Ekso Bionics from $10.00 to $9.00 and set a “buy” rating for the company in a research report on Tuesday, October 29th. Lake Street Capital reduced their target price on shares of Ekso Bionics from $2.50 to $2.00 and set a “buy” rating for the company in a report on Tuesday, October 29th.

Ekso Bionics Trading Up 7.9 %

EKSO opened at $0.83 on Monday. Ekso Bionics has a 52 week low of $0.50 and a 52 week high of $3.03. The company has a market capitalization of $18.26 million, a P/E ratio of -1.28 and a beta of 1.47. The stock’s fifty day moving average is $0.71 and its two-hundred day moving average is $0.97. The company has a quick ratio of 2.14, a current ratio of 2.81 and a debt-to-equity ratio of 0.28.

Ekso Bionics (NASDAQ:EKSO) last announced its quarterly earnings results on Monday, October 28th. The company reported ($0.10) EPS for the quarter, missing the consensus estimate of ($0.08) by ($0.02). The firm had revenue of $4.13 million for the quarter, compared to analysts’ expectations of $6.00 million. Ekso Bionics had a negative net margin of 62.95% and a negative return on equity of 83.09%. During the same quarter in the prior year, the business posted ($0.24) EPS. Analysts forecast that Ekso Bionics will post -0.48 earnings per share for the current year.

Ekso Bionics Company Profile

Ekso Bionics Holdings, Inc designs, develops, sells, and rents exoskeleton products in the Americas, Germany, Poland, Europe, the Middle East, Africa, the Asia Pacific, and internationally. It operates in two segments, EksoHealth and EksoWorks. The EksoHealth segment designs, engineers, manufactures, and markets exoskeletons for applications in the medical markets.